NCT07295496
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetic of IBI3011
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 16 words Show 4 more changesShow less
- Trial completed
- Primary completion date changed from estimate of Jun 7, 2026 to Aug 6, 2026
- Study completion date changed from estimate of Jun 7, 2026 to Sep 28, 2026
- Secondary endpoints: details revised at 4 of 6 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timeframe: 12 week
Secondary (6)
Immunogenic outcome
AUC
Cmax
CL or CL/F
V or V/F
Show 1 moreShow less
t1/2
Arms and interventions
PlaceboPlacebo comparator
IBI3011 placebo group
IBI3011Experimental
IBI3011 group
Drugs: IBI3011, IBI3011 Placebo
Sites
1 site in 1 country
- The First Affiliated Hospital of Soochow UniversitySuzhou, Jiangsu, China